EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische StudieBeobachtungsstudie

Efficacy and safety of catheter ablation for paroxysmal atrial fibrillation: A comparison of first-line vs second-line therapy

Jun Oikawa, Hidehira Fukaya, Koshiro Kanaoka, Shinichi Niwano, Koji Miyamoto, Yoshitaka Iwanaga, Yu-Ki Iwasaki, Koichi Nagashima, Masaharu Masuda, Seigo Yamashita, Kohki Nakamura, Kazuhiro Satomi und 6 weitere

Heart Rhythm · 2025

DOI: 10.1016/j.hrthm.2025.07.030 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Heart Rhythm, 2025. Verfasst von Jun Oikawa und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Kitasato Clinical Research Center, Kitasato University School of Medicine, Sagamihara, Japan; Department of Cardiovascular Medicine, Ki…. Hauptthemen laut MEDLINE: Atrial Fibrillation, Catheter Ablation, Registries. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Catheter ablation (CA) is an effective rhythm control therapy for atrial fibrillation (AF). Recent advancements have improved its efficacy and safety. From 2022 to 2024, guidelines in the United States, Japan, and Europe classify CA as a Class I recommendation for paroxysmal AF (PAF) as a first-line therapy. Previously, CA was recommended as Class I only for the patient refractory to drug therapy. Despite these updates, direct comparative studies between first-line CA and second-line CA remain limited. OBJECTIVE: This study aimed to evaluate the efficacy and safety of CA as first-line versus second-line therapy using data from the Japan Nationwide Ablation (J-AB) registry. METHODS: We analyzed patients with PAF who underwent CA from 2017 to 2020 in the J-AB registry. Patients were categorized into a First-line group (CA without prior antiarrhythmic drug [AAD]) and a Second-line group (CA following AAD failure). Efficacy was assessed by recurrence of atrial tachyarrhythmia within 1 year after a 90-day blanking period. Safety was evaluated based on major complications, including severe bleeding, stroke, and gastrointestinal disorders. RESULTS: Among 5011 patients (median age 69 years, 35% were women), baseline characteristics were similar between groups except for beta-blocker use. Recurrence rates were comparable (10.0% overall; log-rank P = .49), and Cox regression showed no significant difference in efficacy (adjusted hazard ratio: 1.06, 95% confidence interval: 0.88-1.28, P = .55). Safety outcomes were also similar. CONCLUSION: First-line CA for PAF demonstrated similar efficacy and safety to second-line CA within 1 year. The registry was registered with the University Hospital Medical Information Network Clinical Trial Registry (UMIN 000028288) and ClinicalTrials.gov (NCT03729232).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationCatheter AblationRegistriesAgedFemaleHumansMaleMiddle AgedAnti-Arrhythmia AgentsFollow-Up StudiesJapanRecurrenceRetrospective StudiesTreatment Outcome

Stichwörter der Autor:innen

Catheter ablationEfficacyFirst-line therapyGuidelineParoxysmal atrial fibrillationReal-world dataRegistry studySafety

Substanzen

Anti-Arrhythmia Agents

Autor:innen und Institutionen

  • Department of Kitasato Clinical Research Center, Kitasato University School of Medicine, Sagamihara, Japan; Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan.
  • Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan. Electronic address: hidehira@med.kitasato-u.ac.jp.
  • Department of Medical and Health Information Management, National Cerebral and Cardiovascular Center, Osaka, Japan. Electronic address: kanaokak@ncvc.go.jp.
  • Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan.
  • Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan.
  • Department of Medical and Health Information Management, National Cerebral and Cardiovascular Center, Osaka, Japan; Department of Cardiology, Sakurabashi-Watanabe Advanced Healthcare Hospital, Osaka, Japan.

Zitieren

APA

Oikawa, J., Fukaya, H., Kanaoka, K., Niwano, S., Miyamoto, K., Iwanaga, Y., Iwasaki, Y. K., Nagashima, K., Masuda, M., Yamashita, S., Nakamura, K., Satomi, K., Takatsuki, S., Inoue, K., Kusano, K., Yamane, T., Tada, H., & Shimizu, W. (2025). Efficacy and safety of catheter ablation for paroxysmal atrial fibrillation: A comparison of first-line vs second-line therapy. Heart Rhythm. https://doi.org/10.1016/j.hrthm.2025.07.030

Vancouver

Oikawa J, Fukaya H, Kanaoka K, Niwano S, Miyamoto K, Iwanaga Y, et al. Efficacy and safety of catheter ablation for paroxysmal atrial fibrillation: A comparison of first-line vs second-line therapy. Heart Rhythm. 2025. doi:10.1016/j.hrthm.2025.07.030

BibTeX
@article{Oikawa2025,
  author = {Oikawa, Jun and Fukaya, Hidehira and Kanaoka, Koshiro and Niwano, Shinichi and Miyamoto, Koji and Iwanaga, Yoshitaka and Iwasaki, Yu-Ki and Nagashima, Koichi and Masuda, Masaharu and Yamashita, Seigo and Nakamura, Kohki and Satomi, Kazuhiro and Takatsuki, Seiji and Inoue, Koichi and Kusano, Kengo and Yamane, Teiichi and Tada, Hiroshi and Shimizu, Wataru},
  title = {Efficacy and safety of catheter ablation for paroxysmal atrial fibrillation: A comparison of first-line vs second-line therapy},
  journal = {Heart Rhythm},
  year = {2025},
  doi = {10.1016/j.hrthm.2025.07.030}
}
Kostenlos starten →